삼양바이오팜

0120G0KOSPISector: Pharma & Biotech

₩40,050▼ 2.32%Market cap ₩297.8BAs of Jul 21, 2026 close · updated once daily

Grade B58.7 ptsTop 37% of 2,523 stocks

Financial strength

60.6

Price attractiveness

56.5

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

ⓘ Growth momentum not rated — will be included automatically as data accumulates

Financial strength

60.6

How much debt does it carry relative to equity?

Debt-to-equity ratio

44.5%

✓ Above median · Top 43.3% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

168.4%

✗ Below median · Top 53.9% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

9.4%

✓ Above median · Top 20.4% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

1.0%

✓ Above median · Top 40% in sector

Sector median -4.5%

Source filing: annual report (separate) — view original ↗

Price attractiveness

56.5

Is the price expensive relative to earnings?

P/E (price-to-earnings)

133.2x

✓ Above median · Top 38.8% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

1.27x

✓ Above median · Top 48.2% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15